OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Incontinence Among Older Adults

Submission Deadline: November 30, 2022 (Open) Submit Now

Guest Editor

Ron J. Jankowski, PhD

Vice President, Scientific Affairs, Cook MyoSite Inc, 105 Delta Dr, Pittsburgh, PA 15238 USA

Website | E-Mail

Research Interests: Autologous muscle derived cells; incontinence; cell therapies; translational medical and biologic product development


Michael B. Chancellor, MD

Professor and Director of Neurourology, Department of Urology, Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI 84073, USA

Website | E-Mail

Research Interests: Incontinence; neurourology; female urology; urology; stem cell and tissue engineering; drug discovery; lower urinary tract dysfunction; adult autologous muscle-derived stem cells; stress urinary incontinence

About This Topic

As we age, mental and physical well-being and health are central to ensuring full participation in a productive, social and happy life. And yet with increased longevity comes increased incidence of incontinence-associated lower urinary and bowel dysfunction, accompanied by the resultant negative individual and societal impacts.

Incontinence is far from benign and its’ negative impact on healthy and active aging manifests in degradation of quality of life, psychosocial well-being and engagement. Regrettably, it is a condition too often perceived as an inevitable reality of the aging process and consequentially has largely gone unnoticed, unrecognized, undertreated and/or marginalized as a health concern. However, as overall life expectancy and the developed world’s senior population increases, it will become an even more common burden on the health care system. Incontinence has tremendous economic impacts in terms of care and support, symptom management, and reductions in economic productivity. Importantly, it is also associated with lack of independent functioning and is often an impetus in the initiation of assisted living and specialized care.

It is hoped that awareness and recognition of the seriousness of incontinence will drive research toward innovations in more effective treatments with fewer or less serious side effects, and could initiate a larger change in current views toward the need for increased diagnosis and treatment, improving the lives of millions of people worldwide.